

Ravi P. Barnwal,^a Wesley C. Van Voorhis^{b,c} and G. Varani^{d*}^aDepartment of Chemistry, University of Washington, Seattle, WA 98195, USA, ^bSeattle Structural Genomics Center for Infectious Disease (SSGCID), USA, ^cDepartment of Medicine, University of Washington, Seattle, WA 98195-6423, USA, and ^dDepartment of Chemistry and Biochemistry, University of Washington, Seattle, WA 98195, USACorrespondence e-mail:
varani@chem.washington.eduReceived 1 November 2010
Accepted 5 February 2011

PDB Reference: BobuA.00658.a, 2kwl.

NMR structure of an acyl-carrier protein from *Borrelia burgdorferi*

Nearly complete resonance assignment and the high-resolution NMR structure of the acyl-carrier protein from *Borrelia burgdorferi*, a target of the Seattle Structural Genomics Center for Infectious Disease (SSGCID) structure-determination pipeline, are reported. This protein was chosen as a potential target for drug-discovery efforts because of its involvement in fatty-acid biosynthesis, an essential metabolic pathway, in bacteria. It was possible to assign >98% of backbone resonances and >92% of side-chain resonances using multidimensional NMR spectroscopy. The NMR structure was determined to a backbone r.m.s.d. of 0.4 Å and contained four α -helices and two 3_{10} -helices. A structure-homology search revealed that this protein is highly similar to the acyl-carrier protein from *Aquifex aeolicus*.

1. Biological context


Borrelia burgdorferi is a Gram-negative bacterium and a cause of Lyme disease. It was isolated and cultured in the 1980s and was named after its discoverer (Burgdorfer *et al.*, 1982). Its complete genome sequence was reported in the late 1990s (Fraser *et al.*, 1997) and provided clues to the role of different genes in the pathogenesis, prevention and treatment of Lyme disease (Guidoboni *et al.*, 2006). Interestingly, this pathogenic bacterium can survive without iron and this property appears to be an important factor in its survival. We selected an acyl-carrier protein, BobuA.00658.a, from *B. burgdorferi* for structure determination within the SSGCID pipeline. This protein is important in fatty-acid biosynthesis. Because of considerable mechanistic and structural differences from the same processes in eukaryotes, enzymes in this pathway represent attractive anti-bacterial targets. The acyl-carrier protein is a universal and highly conserved carrier of acyl intermediates during fatty-acid biosynthesis. In yeast, these proteins exist as separate domains within a large multifunctional fatty-acid synthases polyprotein, whereas in bacteria they are mostly monomeric proteins. These proteins are also cofactors of various primary and secondary pathways, including signaling and production of natural bioactive products. For these reasons, these proteins are interesting drug targets for novel antibacterials and a structure was pursued within SSGCID.

The structures of several acyl-carrier proteins from different organisms have been reported. However, no acyl-carrier protein has been studied from *B. burgdorferi*. In this manuscript, we report almost complete resonance assignment and the high-resolution NMR structure of the acyl-carrier protein from *B. burgdorferi*.

2. Methods and experiments

2.1. Cloning, protein overexpression and sample preparation

The gene coding for the acyl-carrier protein (UniProt ID O51647; entry name ACP_BORBU) was amplified from the genomic DNA of *B. burgdorferi* using standard PCR techniques. The protein will also be referred to as BobuA.00658.a, its SSGCID identifier. The amplified product was cloned into pET-AVA vector, a modified pET28 vector. The expression construct was transformed into Rosetta



calculations started with 100 randomized conformers. Of all the energy-minimized calculated structures, the 20 structures with the lowest residual target function values were chosen for further analyses. All-atom pairwise r.m.s.d.s were also computed using *CYANA2.1* (Güntert, 2004) and *MOLMOL* (Koradi *et al.*, 1996). The quality of the structures was evaluated using *PROCHECK* (Laskowski *et al.*, 1996) and the *PSVS* 1.3 web server (Bhattacharya *et al.*, 2007). The structure was deposited in the PDB under code 2kwl.

3. Result and discussion

3.1. NMR assignments and data deposition

The BobuA.00658.a protein is free of Cys, His and Trp residues. We could assign ~98% of observable backbone resonances and >92% of observable side-chain resonances using triple-resonance experiments as described in §2. The $^1\text{H}^{\text{N}}$ and ^{15}N resonance assignments for the protein are shown by the single-letter code followed by the sequence number in the ^{15}N - ^1H -HSQC (Fig. 1). The three NH resonances (Arg34, Ile61 and Glu70) are shifted downfield owing to their involvement in hydrogen bonding. These residues may have a func-

tional role in catalysis, but we have not investigated this role using site-directed mutagenesis. A clearer picture in terms of function and its relation to these residues would require further biochemical experiments. The missing backbone amide resonances consist of two residues in the N-terminal region of the protein which are broadened beyond detection. The information about the ^1H , ^{13}C and ^{15}N resonance assignments thus obtained for the protein has been deposited in the BMRB under accession code 16856.

3.2. NMR solution structure of BobuA.00658.a

The NMR structure of BobuA.00658.a was determined using distance constraints and dihedral constraints as detailed in Table 1. Fig. 2 shows the ensemble of 20 superimposed structures derived using *CYANA*. The quality of the structure was verified with *PROCHECK* (Laskowski *et al.*, 1996), which revealed that none of the residues lie in disallowed regions of the Ramachandran plot. The structural and Ramachandran statistics for BobuA.00658.a are also provided in Table 1. The polypeptide segments consisting of residues 7–22, 34–37, 43–57 and 72–83 form four α -helices, whereas segments




Figure 2 NMR structure of BobuA.00658.a. (a) Ensemble of 20 superimposed low-energy NMR-derived structures of the protein (backbone r.m.s.d. = 0.43 ± 0.11 Å) in ribbon representation. (b) Cartoon representation; important residues in the hydrophobic core are shown in purple color with their respective sequence number. Images were generated using *PyMOL* (<http://www.pymol.org>).




Figure 3 Sequence alignment of the acyl-carrier protein from *B. burgdorferi* compared with related acyl-carrier proteins from different prokaryotic organisms: *S. thermophilum*, *A. aeolicus*, *P. marinus* and *C. thermocellum*. The alignment was produced using *ESPrpt* 2.2 (<http://esprpt.ibcp.fr/ESPrpt/ESPrpt/>). Residues with high sequence similarity and identity are shown in closed boxes and as colored regions, respectively. The secondary structures from PDB entry 2kwl are shown at the top of the figure.

26–28 and 65–68 form 3_{10} -helices. Within the inner face of the helices, several hydrophobic side chains form the core of the protein (Fig. 2*b*).

Sequence alignment with the enzymes from *Symbiobacterium thermophilum*, *Aquifex aeolicus*, *Prochlorococcus marinus* and *Clostridium thermocellum* revealed that BobuA.00658.a has 48% sequence similarity to the enzyme from *S. thermophilum*, 44% to that from *A. aeolicus*, 52% to that from *P. marinus* and 58% to that from *C. thermocellum* (Fig. 3). A structural homology search using the DALI server (http://ekhidna.biocenter.helsinki.fi/dali_server) revealed that this protein has 37% similarity to the acyl-carrier protein from *A. aeolicus*, which is structurally closest to it. The backbone r.m.s.d. between the structures from *A. aeolicus* and *B. burgdorferi* was 3.1 Å, whereas alignments of BobuA.00658.a with structures from other organisms had higher values. Only residues 8–82 of BobuA.00658.a were selected for r.m.s.d. comparison. Based on the UniProt and homology search, Ser39 seems to be a central residue involved in fatty-acid binding. This residue is close to the core involving three downfield-shifted residues (Arg34, Ile61 and Glu70). Finally, a proper study including mutation *in vivo* will provide a clearer picture regarding fatty-acid binding.

4. Conclusions

We report here the structure of an acyl-carrier protein from *B. burgdorferi*. Since this protein was selected as a potential target for drug-discovery efforts (Myler *et al.*, 2009; Younger & Orsher, 2010) owing to its involvement in fatty-acid biosynthesis, its structural and dynamic features could be used to better understand its acyl-carrier activity and to discover inhibitors of its essential function. This information could be of value in discovering small-molecule inhibitors for this activity, which could be used in the treatment of Lyme disease.

The authors wish to thank all the members of the SSGCID team. This research was funded under the Federal Contract No. HHSN272200700057C from the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, Department of Health and Human Services. A portion of the research was performed using EMSL, a national scientific user facility sponsored by the Department of Energy's Office of Biological and Environmental Research and located at Pacific Northwest National Laboratory.

References

- Barnwal, R. P., Rout, A. K., Chary, K. V. & Atreya, H. S. (2007). *J. Biomol. NMR*, **39**, 259–263.
- Bhattacharya, A., Tejero, R. & Montelione, G. T. (2007). *Proteins*, **66**, 778–795.
- Burgdorfer, W., Barbour, A. G., Hayes, S. F., Benach, J. L., Grunwaldt, E. & Davis, J. P. (1982). *Science*, **216**, 1317–1319.
- Delaglio, F., Grzesiek, S., Vuister, G. W., Zhu, G., Pfeifer, J. & Bax, A. (1995). *J. Biomol. NMR*, **6**, 277–293.
- Fraser, C. M. *et al.* (1997). *Nature (London)*, **390**, 580–586.
- Guidoboni, M., Ferreri, A. J., Ponzoni, M., Doglioni, C. & Dolcetti, R. (2006). *Clin. Lymphoma Myeloma*, **6**, 289–300.
- Güntert, P. (2004). *Methods Mol. Biol.* **278**, 353–378.
- Koradi, R., Billeter, M. & Wüthrich, K. (1996). *J. Mol. Graph.* **14**, 51–55.
- Laskowski, R. A., Rullmann, J. A., MacArthur, M. W., Kaptein, R. & Thornton, J. M. (1996). *J. Biomol. NMR*, **8**, 477–486.
- Myler, P. J., Stacy, R., Stewart, L., Staker, B. L., Van Voorhis, W. C., Varani, G. & Buchko, G. W. (2009). *Infect. Disord. Drug Targets*, **9**, 493–506.
- Shen, Y., Delaglio, F., Cornilescu, G. & Bax, A. (2009). *J. Biomol. NMR*, **44**, 213–223.
- Vranken, W. F., Boucher, W., Stevens, T. J., Fogh, R. H., Pajon, A., Llinas, M., Ulrich, E. L., Markley, J. L., Ionides, J. & Laue, E. D. (2005). *Proteins*, **59**, 687–696.
- Younger, D. S. & Orsher, S. (2010). *Neurol. Res. Int.* **2010**, 525206.